Table 3 Validation of the MBCSIM model in 108 ER-positive breast cancer patients for a follow-up period of 5 years
Validation database | Simulation (mean±s.d.) | |
|---|---|---|
Initial imaging tests | ||
116 | 104.0±6.5 | |
BS and X-bone | 53 | 52.2±3.8 |
MRI bone | 8 | 15.3±2.2 |
FDG-PET/CT | 3 | 1.2±0.3 |
X-ray lung | 31 | 16.9±0.8 |
CT lung/liver | 7 | 2.0±0.4 |
Ultrasound liver | 7 | 7.0±0.3 |
MRI liver | 0 | 0.2±0.1 |
MRI brain | 7 | 9.2±2.5 |
FES-PET/CT | 0 | 0.0±0.0 |
Staging tests | ||
13 | 17.9±1.3 | |
CT lung+CT liver | 5 | 11.3±1.0 |
BS+CT lung+CT liver | 8 | 6.6±0.9 |
Biopsy tests | ||
18 | 20.3±1.5 | |
Bone | 6 | 7.4±1.0 |
Lung | 10 | 5.6±0.5 |
Liver | 0 | 3.3±0.2 |
Brain | 2 | 4.0±1.0 |
MBCs found | ||
14 | 10.2±1.0 | |
Bone | 8 | 3.7±0.6 |
Lung | 3 | 2.7±0.3 |
Liver | 2 | 2.6±0.2 |
Brain | 1 | 1.2±0.3 |
